Anthony Doyle

Chief Financial Officer, BioCryst Pharmaceuticals.

Companies

BioCryst PharmaceuticalsChief financial officer Apr 8, 2020 to Dec 23, 2024¹

Stock this person has reported owning, from the forms officers and directors file with the SEC. See the biggest insider stakes.

As of each latest filing. The line shows shares held over time.

Dec 19, 2024Shares withheld for tax 2,461 shares at $7.39 of BioCryst Pharmaceuticals²
Dec 19, 2024Granted 120,700 shares of BioCryst Pharmaceuticals²
Dec 14, 2024Shares withheld for tax 7,890 shares at $7.53 of BioCryst Pharmaceuticals³
May 14, 2024Bought 36,300 shares at $5.57 of BioCryst Pharmaceuticals⁴
Dec 19, 2023Shares withheld for tax 2,482 shares at $6.05 of BioCryst Pharmaceuticals⁵
Dec 14, 2023Shares withheld for tax 5,475 shares at $6.43 of BioCryst Pharmaceuticals⁶
Dec 14, 2023Granted 34,000 shares of BioCryst Pharmaceuticals⁶
Dec 19, 2022Granted 34,000 shares of BioCryst Pharmaceuticals⁷
Dec 15, 2022Sold 5,700 shares at $10.90 of BioCryst Pharmaceuticals⁸
Dec 14, 2021Granted 115,000 shares of BioCryst Pharmaceuticals⁹
Dec 14, 2021Granted 75,000 shares of BioCryst Pharmaceuticals¹⁰
Nov 23, 2021Bought 35,258 shares at $12.48 of BioCryst Pharmaceuticals¹¹

The numbers on this page point here. Each one links to the record it came from.